Newly Approved RSV Vaccine

The Food and Drug Administration approved the first-ever vaccine to combat severe respiratory syncytial virus, or RSV. 

Arexvy, the new vaccine developed by GlaxoSmithKline, was approved for adults 60 years and older and is 82% effective at preventing lower respiratory tract illness caused by RSV.

FDA approves first-ever RSV vaccine, shots to be available for older adults